Project Grant T32CA285265

Award Date 1/15/25
Completion Date 12/31/29
Dollars Obligated $179K
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Oregon, USA
Similar Awards
This Project Grant award of $432,326 from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports the Translational Cancer Biology (TCB) T32 Training Program at the University of Texas Southwestern Medical Center. The program aims to train pre-doctoral and post-doctoral scientists in conducting independent cancer research, fostering their intellectual, technical, and communication skills for success in academic or industry settings. The award provides funding...
This Project Grant award of $145,937 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports the Huntsman Cancer Institute Oncological Data Science (ODSI) Training Program at the University of Utah. The program provides a two-year predoctoral training program that integrates cancer biology, bioinformatics, epidemiology, and data science to prepare young scientists to become experts in leveraging data science techniques to advance cancer research, prevention,...
This federal Project Grant award for $166,428 from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) will support a new T32 predoctoral training program at Stanford University to prepare the next generation of multi-disciplinary cancer researchers. The program, titled "Genetic and Environmental Basis of Cancer Risk and Disparities (GECARD)," will provide integrative training across fields like epidemiology, biostatistics, genetics, environmental health, and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $193,144 to The Trustees of Columbia University in the City of New York to support a multidisciplinary postdoctoral training program focused on gastrointestinal (GI) cancers. The 5-year program, running from September 1, 2024 to August 31, 2029, aims to train the next generation of GI cancer researchers across basic science, translational, clinical, epidemiological, and...
This Project Grant award of $315,143.00 from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports clinical trial research in the oncology landscape. The award, which has an ultimate completion date of August 31, 2029, is being provided to The Ohio State University, a leading public research university. Through this funding, The Ohio State University will conduct innovative cancer research focused on understanding cancer mechanisms, developing new diagnostic and...
The University of Texas Health Science Center at San Antonio (UTHSCSA) was awarded a $358,528 Project Grant under the Cancer Research Manpower (CFDA 93.398) program by the National Cancer Institute, a component of the National Institutes of Health. The 5-year grant, effective September 1, 2024, will support the EPIGENETICS, DNA REPAIR AND GENOMICS (EDGE) TRAINING PROGRAM IN CANCER. This program will provide cross-disciplinary training to 4 predoctoral students per year in the areas of cancer...
The University of California, Los Angeles (UCLA) was awarded a $1,036,293 federal Project Grant under the National Cancer Institute's Cancer Research Manpower (CFDA 93.398) program. The grant, effective February 1, 2025 through June 30, 2030, will establish the Neuro-Oncology Translational Research Training Program (NOTR-TP) to support 1 predoctoral and 3 postdoctoral trainees in brain cancer research. The program will provide a comprehensive, multidisciplinary curriculum spanning oncology,...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $132,462 to the Fred Hutchinson Cancer Center in Seattle, WA to support research aimed at improving engineered T cell receptor T cell (TCR-T) therapy for solid tumors. The key objectives are to: 1) Determine why TCR-T cells form a different reservoir of stem-like progenitor cells in tumor-draining lymph nodes compared to endogenous tumor-specific T cells, and 2)...
This Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under CFDA Program 93.350, provides $168,352 to the University of California, Irvine (UCI) to support the "INSTITUTE FOR CLINICAL AND TRANSLATIONAL SCIENCE NRSA POSTDOCTORAL RESEARCH TRAINING CORE" program. The goal of this 5-year program is to provide a robust mentored career development and training environment to equip postdoctoral fellows with the core competencies and advanced...
This federal Project Grant award of $710,004, provided by the National Center for Advancing Translational Sciences (NCATS) under CFDA Program 93.350, will support an innovative 2-year postdoctoral training program called "Equitable Translational Science to Accelerate Impact of New Innovations (E-TRAIN)" at Northwestern University. The program aims to catalyze the careers of postdoctoral scientists by expanding their domain expertise through mentored research and developing foundational...

This federal Project Grant award, ID T32CA285265, was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program. The $178,541 award will fund the "Experimental Therapeutics in Cancer (ETC) Training Program" at Oregon Health & Science University (OHSU), an NCI-designated Comprehensive Cancer Center.

The ETC Training Program will provide a 2-year postdoctoral training program to 9 PhD and MD scientists focused on translating scientific discoveries into new cancer therapies. Trainees will participate in preclinical research projects related to drug discovery, target validation, lead optimization, biomarker development, and testing in preclinical models. They will also receive training in clinical trial design, regulatory requirements, and professional development, including mentoring undergraduate students. The program brings together a multidisciplinary group of 37 experienced faculty researchers to train the next generation of translational oncology investigators capable of advancing novel cancer treatments.

Generated 7/15/25, 3:00 AM